Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

235

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Muscle Invasive Bladder Neoplasms

Interventions

DRUG: Erdafitinib Intravesical Delivery System

Sponsor

Janssen Research & Development, LLC